{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In a recent study on endometrial cancer (uterine corpus endometrial carcinoma, UCEC), a novel prognostic signature composed of 11 long non‐coding RNAs was identified to stratify patients into high‐risk and low‐risk groups with significantly different overall and progression‐free survival outcomes (1). Among these prognostic lncRNAs, GTF3C2‑AS1 appears to play a pivotal role as part of this signature. Its expression, alongside that of the other lncRNAs in the panel, is associated with key tumor suppressor and oncogenic pathways that drive endometrial carcinogenesis. Consequently, GTF3C2‑AS1 may serve as a valuable molecular indicator for predicting patient survival and facilitating individualized treatment planning by complementing conventional clinical covariates."}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Meng Zhou, Zhaoyue Zhang, Hengqiang Zhao, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "BMC Cancer (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1186/s12885-017-3983-0"}], "href": "https://doi.org/10.1186/s12885-017-3983-0"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "29304762"}], "href": "https://pubmed.ncbi.nlm.nih.gov/29304762"}]}]}]}